The test will be reimbursed at the price of $1,495 for Medicare patients during the initial nine-month ADLT period starting on April 1.
NEW YORK – Former Magellan Diagnostics CEO Amy Winslow pleaded guilty to violating the federal Food, Drug and Cosmetic Act in a case related to the malfunctioning of Magellan's lead-testing devices.
The deal is part of BioReference's ongoing effort to streamline its business to achieve profitability and follows the sale last year of clinical laboratory assets to Labcorp.
The collaboration will involve the development of algorithms to aid the assessment of complex and difficult-to-scan samples, including bone marrow biopsies.
The test will be reimbursed at the price of $1,495 for Medicare patients during the initial nine-month ADLT period starting on April 1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback